The biopharma world is still processing the seismic news of Isomorphic Labs’ $2.1 billion Series B […]
Takeda’s savings programme is no longer an abstract investor slide. It has moved from corporate language […]
The JPY 200 billion savings target currently dominating Takeda’s internal dialogue isn’t just a number on […]